Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival.
Nat Immunol
; 18(6): 694-704, 2017 06.
Article
en En
| MEDLINE
| ID: mdl-28369050
ABSTRACT
The transcription factor STAT5 has a critical role in B cell acute lymphoblastic leukemia (B-ALL). How STAT5 mediates this effect is unclear. Here we found that activation of STAT5 worked together with defects in signaling components of the precursor to the B cell antigen receptor (pre-BCR), including defects in BLNK, BTK, PKCß, NF-κB1 and IKAROS, to initiate B-ALL. STAT5 antagonized the transcription factors NF-κB and IKAROS by opposing regulation of shared target genes. Super-enhancers showed enrichment for STAT5 binding and were associated with an opposing network of transcription factors, including PAX5, EBF1, PU.1, IRF4 and IKAROS. Patients with a high ratio of active STAT5 to NF-κB or IKAROS had more-aggressive disease. Our studies indicate that an imbalance of two opposing transcriptional programs drives B-ALL and suggest that restoring the balance of these pathways might inhibit B-ALL.
Texto completo:
1
Colección:
01-internacional
Asunto principal:
Linfocitos B
/
Regulación Neoplásica de la Expresión Génica
/
Proteínas Adaptadoras Transductoras de Señales
/
Factor de Transcripción STAT5
/
Factor de Transcripción Ikaros
/
Leucemia-Linfoma Linfoblástico de Células Precursoras
/
Receptores de Células Precursoras de Linfocitos B
Tipo de estudio:
Prognostic_studies
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Nat Immunol
Asunto de la revista:
ALERGIA E IMUNOLOGIA
Año:
2017
Tipo del documento:
Article
País de afiliación:
Estados Unidos